| Year |
Citation |
Score |
| 2023 |
Kuppers DA, Linton J, Ortiz Espinosa S, McKenna KM, Rongvaux A, Paddison PJ. Gene knock-outs in human CD34+ hematopoietic stem and progenitor cells and in the human immune system of mice. Plos One. 18: e0287052. PMID 37379309 DOI: 10.1371/journal.pone.0287052 |
0.346 |
|
| 2022 |
Chen J, Johnson L, McKenna K, Choi T, Duan J, Feng D, Tsai J, Garcia-Martin N, Sompalli K, Maute R, Vyas P, Majeti R, Takimoto C, Liu J, Ramsingh G, et al. MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). Clinical Lymphoma, Myeloma & Leukemia. S317-S318. PMID 36163968 DOI: 10.1016/S2152-2650(22)01421-5 |
0.609 |
|
| 2022 |
Voillet V, Berger TR, McKenna KM, Paulson KG, Tan WH, Smythe KS, Hunter DS, Valente WJ, Weaver S, Campbell JS, Kim TS, Byrd DR, Bielas JH, Pierce RH, Chapuis AG, et al. An In Vivo Model of Human Macrophages in Metastatic Melanoma. Journal of Immunology (Baltimore, Md. : 1950). PMID 35817516 DOI: 10.4049/jimmunol.2101109 |
0.35 |
|
| 2021 |
Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, Willingham S, Ho PY, Rosental B, Tal MC, Raveh T, Volkmer JP, Pegram MD, Weissman IL. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34257155 DOI: 10.1073/pnas.2026849118 |
0.543 |
|
| 2020 |
Kiss B, Volkmer AK, Feng D, McKenna KM, Mihardja S, Chao M, Takimoto CH, Liao JC, Volkmer J, Weissman IL. Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer. Journal of Clinical Oncology. 38: e17035-e17035. DOI: 10.1200/Jco.2020.38.15_Suppl.E17035 |
0.5 |
|
| 2019 |
Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, Majeti R. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology. 9: 1380. PMID 32038992 DOI: 10.3389/Fonc.2019.01380 |
0.604 |
|
| 2019 |
Kiss B, van den Berg NS, Ertsey R, McKenna K, Mach KE, Zhang CA, Volkmer JP, Weissman IL, Rosenthal EL, Liao JC. CD47-targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30890547 DOI: 10.1158/1078-0432.CCR-18-3267 |
0.596 |
|
| 2018 |
Tsai JM, Sinha R, Seita J, Fernhoff N, Christ S, Koopmans T, Krampitz GW, McKenna KM, Xing L, Sandholzer M, Sales JH, Shoham M, McCracken M, Joubert LM, Gordon SR, et al. Surgical adhesions in mice are derived from mesothelial cells and can be targeted by antibodies against mesothelial markers. Science Translational Medicine. 10. PMID 30487249 DOI: 10.1126/Scitranslmed.Aan6735 |
0.376 |
|
| 2018 |
Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84. PMID 29180808 DOI: 10.1038/S41590-017-0004-Z |
0.532 |
|
| 2018 |
Feng D, Gip P, McKenna KM, Zhao F, Mata O, Choi TS, Duan J, Sompalli K, Majeti R, Weissman IL, Takimoto CH, Chao MP, Chen JY, Liu J, Volkmer J. Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia Blood. 132: 2729-2729. DOI: 10.1182/Blood-2018-99-120170 |
0.477 |
|
| 2018 |
Chen JY, McKenna KM, Choi TS, Duan J, Brown L, Stewart JJ, Sompalli K, Vyas P, Schrier S, Majeti R, Weissman IL, Elrod K, Chao MP, Takimoto CH, Liu J, et al. RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9 Blood. 132: 2327-2327. DOI: 10.1182/Blood-2018-99-115674 |
0.614 |
|
| 2018 |
Kiss B, McKenna K, Ertsey R, Van den Berg NS, Mach K, Rosenthal E, Liao J. MP65-09 NEAR INFRARED PHOTOIMMUNOTHERAPY USING ANTI-CD47 ANTIBODY FOR HUMAN BLADDER CANCER Journal of Urology. 199. DOI: 10.1016/j.juro.2018.02.2075 |
0.489 |
|
| 2017 |
Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A, Zheng Y, Ring AM, Flavell RA, Weissman IL. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. PMID 29158380 DOI: 10.1073/Pnas.1710877114 |
0.58 |
|
| 2017 |
Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, Kuo AH, McKenna K, Kojima Y, Leeper NJ, Ho P, Gip P, Swigut T, Sherwood RI, Clarke MF, et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nature Communications. 8: 14802. PMID 28378740 DOI: 10.1038/Ncomms14802 |
0.61 |
|
| 2016 |
Weiskopf K, Anderson KL, Ito D, Schnorr PJ, Tomiyasu H, Ring AM, Bloink K, Efe J, Rue S, Lowery D, Barkal A, Prohaska S, McKenna KM, Cornax I, O'Brien TD, et al. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20. Cancer Immunology Research. PMID 27856424 DOI: 10.1158/2326-6066.Cir-16-0105 |
0.623 |
|
| 2016 |
Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, Schadt EE, Quertermous T, Betancur P, Maegdefessel L, Matic LP, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. PMID 27437576 DOI: 10.1038/Nature18935 |
0.517 |
|
| 2015 |
Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, McKenna KM, Cheshier S, Zhang M, Guo N, Gip P, Mitra SS, Weissman IL. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proceedings of the National Academy of Sciences of the United States of America. 112: 2145-50. PMID 25646432 DOI: 10.1073/Pnas.1424907112 |
0.554 |
|
| Show low-probability matches. |